The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
News|Articles|September 7, 2022
COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of September 7, 2022
Author(s)Sydney Jennings
Advertisement
US COVID-19 vaccination & booster dose status
US COVID-19 vaccination status according to the Centers for Disease Control and Prevention (CDC) as of September 1, 2022, at 6:00 AM, EDT:
Fully vaccinated plus 2 booster doses:
• Aged ≥50 years 34%
• Aged ≥65 years 41.2%
Fully vaccinated plus 1 booster dose:
• Total US population 48.5%
Fully vaccinated in key age groups:
• Total US population 67.5%
• Aged ≥5 years 71.7%
• Aged ≥65 years 92.1%
US confirmed cases of COVID-19 and deaths
Confirmed US cases of COVID-19 and related deaths according to the Johns Hopkins COVID-19 interactive map , as of September 7, 2022 at 2:20 PM, EDT.
3 states with highest number of new cases in past 28 days
• California 283 781
• Texas 235 554
• Florida 167 190
• Total US confirmed cases 94 956 887
• Total US confirmed deaths 1 048 522
Global total COVID-19 confirmed cases, deaths, vaccine doses administered:
• Cases 606 658 877
• Deaths 6 507 002 • Vaccine doses administered 12 182 521 701
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.
Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
2
New Study Shows Menopause Undercoded in Primary Care, With Gaps by Race and Insurance
3
Contraindicated Hormone Therapy Prescribing Climbs in Primary Care
4
Retatrutide Phase 3 Trials Report Reduced Knee Osteoarthritis Pain
5